SCHEMBL4045377

SCHEMBL4045377

Nc1nc(Nc2ccc(CN3CCOCC3)cc2)nn1-c1ccccc1F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.59
FLT3 P36888 6/20 0.53
AURKA O14965 1/20 0.52
AURKB Q96GD4 1/20 0.52
KIT P10721 3/20 0.49
NPC1 O15118 1/20 0.47
TP53 P04637 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
AXL P30530 1/20 0.46
PLK4 O00444 1/20 0.46
ALDH1A1 P00352 2/20 0.45
EGFR P00533 2/20 0.45
USP2 O75604 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
CDK1 P06493 1/20 0.45
CDK2 P24941 1/20 0.45
JAK2 O60674 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4040246 0.89 FLT3 (0.52) BACE1FLT3KITPLK4ALDH1A1
SCHEMBL4038690 0.85 FLT3 (0.67) BACE1FLT3AURKAAURKBKIT
SCHEMBL4037761 0.82 FLT3 (0.74) BACE1FLT3AURKAKITAXL
SCHEMBL4039530 0.76 BACE1 (0.61) BACE1FLT3KITAXL
SCHEMBL28335490 0.74 FLT3 (0.61) BACE1FLT3AURKAAURKBKIT
SCHEMBL29929743 0.74 BACE1 (1.00) BACE1AXL
SCHEMBL4238335 0.74 BACE1 (1.00) BACE1AXL
SCHEMBL29928963 0.73 BACE1 (1.00) BACE1AXL
SCHEMBL4990459 0.73 BACE1 (1.00) BACE1AXL
SCHEMBL4044785 0.73 AXL (0.53) BACE1FLT3KITAXLPLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885FLT3 220/4885AURKA 181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.